InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Key Highlights
- ➤Mentari merger targets Q4 2026 close; shareholders vote November 4
- ➤Mentari private placements total approximately US$490 million for operations into 2029
- ➤Nasdaq grants InMed until March 15, 2027, to regain compliance
- ➤Cash $1.0 million; runway extends only into mid-November
- ➤Q1 net loss $2.33 million versus $1.73 million prior year
Expert Statements
Eric A. Adams, President and CEO of InMed Pharmaceuticals
“We are approaching an important milestone in our proposed merger with Mentari Therapeutics, with our annual general and special meeting scheduled for November 4, 2026,”
Eric A. Adams, President and CEO of InMed Pharmaceuticals
“Our focus remains on completing the transaction, which we believe provides shareholders with an opportunity to participate in the development of Mentari's migraine prevention pipeline.”
Eric A. Adams, President and CEO of InMed Pharmaceuticals
“In parallel, we continue to pursue opportunities to realize value from InMed's legacy pharmaceutical assets for our shareholders through the proposed contingent value rights structure.”
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update.
The Company's full financial statements and related MD&A for the quarter ended September 30, 2026, are available at www.inmedpharma.com, www.sedarplus.ca and www.sec.gov.
Get started
Create a free account to read the full story.